Skip To Main Content
Susanne Bard on Muck Rack

Susanne Bard

Verified
San Diego
As seen in: San Diego State University Magazine, MSN, Scientific American, UC SAN DIEGO, Medical Xpress, University of California, The Sierra Sun Times, Targeted News Service
Science writer & multimedia producer. #scicomm @SDSU. #evolution #birds #conservation #history #neuroscience #engineering. Views my own.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Susanne

Contact Susanne, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Personalized Gene Therapy Helps Teen with Rare Form of Severe Epilepsy Walk Independently

|
By Susanne Bard Verified, Lizelda Lopez
| UC SAN DIEGO
Published Date July 21, 2026 Investigational gene therapy with allele-selective antisense oligonucleotides silenced the expression of a mutant copy of the SCN2A gene, dramatically reducing seizure frequency. Broad developmental gains were observed across a two-year period, with no adverse health effects reported. The approach provides a model for rapidly translating personalized genetics into treatments for many other neurological and non‑neurological diseases caused by single gene mutations.
Open in Who Shared View Duplicates (5) Issue with article?

Popular GLP-1 drug may slow down biological aging, analysis indicates

|
By Susanne Bard Verified, Sadie Harley, Andrew Zinin Verified
| Medical Xpress Verified
Credit: Unsplash/CC0 Public Domain Glucagon-like peptide-1 (GLP-1) receptor agonist medications have gained widespread attention for effectively treating obesity, lowering blood sugar and decreasing the risk of cardiovascular disease. Some researchers have proposed that these drugs may also influence the biology of aging, but direct evidence in humans has remained limited.
Open in Who Shared View Duplicates (4) Issue with article?

Study: Popular GLP-1 Drug May Slow Down Biological Aging

|
By Susanne Bard Verified
| UC SAN DIEGO
Published Date June 02, 2026 Semaglutide slowed biological aging across multiple epigenetic clocks in a randomized, double-blind, placebo-controlled clinical trial. The strongest signals were seen in epigenetic measures linked to inflammation, brain, heart, blood, kidney, liver and metabolic health, suggesting that the drug may influence aging-related biology across multiple body systems. The findings offer early clinical evidence that GLP-1 receptor agonists may influence aging biology.
Open in Who Shared View Duplicates (7) Issue with article?
See all 138 articles